A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

NCT04161898 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Takayasu Arteritis (TAK)

Interventions

DRUG: Upadacitinib
DRUG: Placebo for Upadacitinib
DRUG: Prednisolone

Sponsor

AbbVie